RM-HNSCC

Bibliography

  1. Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., Castro, G. de, Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. W., Hong, R.-L., Mendoza, R. G., Roy, A., … Yorio, J. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. The Lancet, 394(10212), 1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7
  2. Cabezas-Camarero, S., Merino-Menéndez, S., Cabrera-Martín, M. N., Sotelo, M. J., Plaza-Hernández, J. C., Falahat, F., Iglesias-Moreno, M. C., & Pérez-Segura, P. (2022). Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. Oncology Letters, 25(1), 37. https://doi.org/10.3892/ol.2022.13623
  3. Dzienis, M. R., Cundom, J. E., Fuentes, C. S., Hansen, A. R., Nordlinger, M. J., Pastor, A. V., Oppelt, P., Neki, A., Gregg, R. W., Lima, I. P. F., Franke, F. A., Junior, G. F. da C., Tseng, J. E., Loree, T., Joshi, A. J., Mccarthy, J. S., Naicker, N., Sidi, Y., Gumuscu, B., & Castro, G. D. (2022). 651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Annals of Oncology, 33, S839–S840. https://doi.org/10.1016/j.annonc.2022.07.775
  4. Harrington, K. J., Burtness, B., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Brana, I., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Lin, J., Gumuscu, B., … Rischin, D. (2023). Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41(4), 790–802. https://doi.org/10.1200/JCO.21.02508
  5. Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., Muro, K., Geva, R., Chung, H. C., Lin, C.-C., Aurora-Garg, D., Ray, A., Pathiraja, K., Cheng, J., Chow, L. Q. M., & Haddad, R. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 119(2), 153–159. https://doi.org/10.1038/s41416-018-0131-9
  6. Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., Cheng, J. D., & Chow, L. Q. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. The Lancet Oncology, 17(7), 956–965. https://doi.org/10.1016/S1470-2045(16)30066-3
13 / 13